December 22, 2021

Seasons’s Greetings from the Icosagen Team

All of us at Icosagen wish you the best in this holiday season and upcoming year!
Read more ›

December 16, 2021

Omicron variant soon available!

On 26th of November 2021, WHO named B.1.1.529 as Omicron and designated it a variant of concern, on the basis on an advice from WHO’s Technical Advisory Group on Virus Evolution (TAG-VE). Omicron has several mutations impacting it’s behaviour, which is rigorously studied across the globe.
Read more ›

November 11, 2021

ISR Vaccine AB signs collaboration agreement with Icosagen for vaccine pipeline

SR Vaccine AB, a subsidiary of ISR Immune System Regulation Holding (publ), has today signed a collaboration agreement with Icosagen, Estonia, as a natural continuation of the MoU that was previously signed.
Read more ›

August 06, 2021

New laboratory studies suggest that BioBlock® nasal spray provides protection against all major variants of coronaviruses

New laboratory studies with BioBlock® nasal spray suggest that BioBlock works against all major variants of coronaviruses, which the World Health Organization considers to be of most concern. Including the Delta variant, which is currently widespread in Estonia.
Read more ›

May 07, 2021

Icosagen's SARS-CoV-2 Neutralizing Antibody ELISA Kit Is Available for Evaluating Immune Responses to COVID-19 and Carries an IVD CE Mark

Icosagen's SARS-CoV-2 Neutralizing Antibody ELISA Kit Is Available for Evaluating Immune Responses to COVID-19 and Carries an IVD CE Mark The SARS-CoV-2 neutralizing antibody ELISA test provides a qualitative in vitro determination of neutralizing antibodies of SARS-CoV-2 in human serum or plasma to either characterize obtained protective condition from previous encounter with the virus or the developed immune response after vaccination. Because it is possible that Covid-19 disease and SARS-CoV-2 vaccines may induce antiviral immunity only for a limited period of time, the SARS-CoV-2 Neutralizing Antibody ELISA kit allows to determine the duration and efficacy of antibody immunity. In addition, the test allows medical facilities to select highly neutralizing blood serums of patients who have recovered from COVID-19 disease, which then can be used to treat critically ill patients. Icosagen's SARS-CoV-2 Neutralizing Antibody ELISA kit has already played a key role in the development of our BioBlock® nasal spray, which has been developed in collaboration with Estonian researchers and entrepreneurs. BioBlock® is a natural formulation derived from bovine colostrum and contains bovine antibodies to SARS-CoV-2 virus. The current ELISA test will be further developed to detect the presence of protective antibodies against other rapidly spreading and severe SARS-CoV-2 strains, such as the UK (B.1.1.7), South African (B.1.351), Brazilian (P.1) and Indian variants. Recent studies have shown that antibodies to common virus strains currently present in Europe offer less protection against newer strains, especially to Brazilian and South African variants. Thus, from the vaccination strategy and epidemiological point of view, it is important to know which strains the Estonian population have protection and which strains have carry a higher risk of disease. Icosagen Cell Factory OÜ's SARS-CoV-2 Neutralizing Antibody ELISA kit was registered on 16 April 2021. With this, Icosagen has already launched another complete CE-IVD product (CE-marked in vitro diagnostic medical device) in Estonia. The test is intended for professional use only, as laboratory training personnel and special laboratory equipment are required. The development of diagnostics was supported by the Government of Estonia with €100,000 grant.
Read more ›

May 04, 2021

BioBlock®, a Novel Prophylactic Nasal Spray With Antibodies Against SARS-CoV-2 Developed by Icosagen, Has Received Marketing Authorization and Is Available for Sale in Estonia

BioBlock® nasal spray is designed to serve as a prophylactic, supplemental measure to help prevent the spread of the SARS-CoV-2 virus, reduce the infection rate, and avoid extensive restrictions. It is intended be used in conjunction with other preventive measures such as masks, hand hygiene, social distancing, as well as vaccination.   BioBlock® is a natural product derived from bovine colostrum collected from cows hyperimmunized with the SARS-CoV-2 viral spike protein. Bovine colostrum is milk produced by cows within the first few days after giving birth that contains antibodies that provide passive immunity to the newborn calves. BioBlock® is produced from colostrum that, along with other naturally occurring beneficial antibodies, contains antibodies against SARS-CoV-2.  
Read more ›

December 24, 2020

Happy holidays

October 21, 2020

Estonian Biotech Icosagen Has Developed Highly Potent Next-Generation Therapeutic and Preventative Anti-SARS-CoV-2 Neutralizing Antibodies as Promising Drug Candidates for Covid-19

October 12, 2020

KTH protein production with QMCF

September 14, 2020

Icosagen's COVID-19 antibody ELISA test is available for diagnostics with an IVD CE mark 

August 31, 2020

Carlova Consult supports Icosagen’s research and development against COVID-19

March 18, 2020

Icosagen continues to support your research

January 15, 2020

Meet us at PepTalk

December 17, 2019

Season’s Greetings!

December 05, 2019

Meet us at Antibody Engineering & Therapeutics or BioFit partnering events

June 03, 2019

Press release: Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagen’s Patented Mammalian Expression Technology

December 18, 2018

Meet us at PepTalk on 14th-18th of January in San Diego

December 12, 2018

Seasons Greetings!

November 06, 2018

Meet us in November at conventions and expos

October 16, 2018

Meet us at European Antibody Congress 2018 in Basel

September 18, 2018

Meet us at BIO Japan 2018

June 28, 2018

Meet Us at 70th AACC Annual Scientific Meeting in Chicago

May 30, 2018

Meet us at BIO International convention in Boston

December 18, 2017

Seasons Greetings!

October 10, 2017

Meet us at Bio Japan

July 31, 2017

Meet us at AACC 2017 in San Diego

April 18, 2017

Meet Icosagen at PEGS Boston May 1-5

February 09, 2017

Icosagen identified several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay

December 29, 2016

Meet us at PEPTalk 2017

December 19, 2016

Merry christmas!

May 05, 2016

Icosagen AS donates to SA University of Tartu Clinic's Children foundation

April 01, 2016

Icosagen developed anti-human BNDF antibody clone 3C11 played prominent role in Neuroscience and JBC publications.

April 01, 2016

HORIZON 2020 project: PROFILE Innovative Training Network

February 29, 2016

Press release: Icosagen Cell Factory was awarded EUR 1.2 million

January 11, 2016

HybriFree recombinant antibody development article is published

December 18, 2015

Seasons Greetings

September 17, 2015

Icosagen AS has incorporated a US subsidiary – Icosagen Technologies, Inc.

September 04, 2015

Icosagen Cell Factory is participating in 29th NIH Research Festival, September 16-18, 2015 in Bethesda, USA

September 04, 2015

Icosagen Cell Factory is participating first MANF and CDNF Proteins Symposium, September 14-15, San Francisco, California

June 10, 2015

Icosagen Cell Factory is participating in AACC Meeting, July 26–30, Georgia World Congress Center, Atlanta, Georgia

June 10, 2015

Icosagen Cell Factory is participating in the BIO International Convention, June 15-18, 2015, Philadelphia

December 30, 2014

The Icosagen Cell Factory OÜ team is looking for a MARKETING SPECIALIST

December 22, 2014

QMCF Technology to be presented at the CHI's 14th Annual PepTalk conference in San Diego, California

December 19, 2014

Happy Holidays from Icosagen!

October 15, 2014

Icosagen and FIT Biotech Oy begin cooperation to develop anti-ebola vaccines and biological therapeutics

October 02, 2014

Icosagen Cell Factory was titled the Best Entrepreneur of 2013

September 08, 2014

Icosagen's opening ceremony

June 10, 2014

QMCF Technology based CHO/Furin expression cell line is available

May 02, 2014

Icosagen Cell Factory attends to PEGS 2014 in Boston

February 05, 2014

Icosagen Cell Factory presentation at Cell Line Development Conference

February 03, 2014

New premises of Icosagen Group